ITCI
Intra-Cellular Therapies, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Norges Bank ✦ (passive) | 1.94M | n/a | $133.13M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.69M | n/a | $115.52M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | T. Rowe Price ✦ | 1.43M | n/a | $97.83M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Wellington Management ✦ | 1.25M | n/a | $85.81M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 5 | Millennium Management ✦ | 889.10K | n/a | $60.89M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 580.36K | n/a | $39.75M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 7 | Point72 Asset Management ✦ | 554.19K | n/a | $37.96M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | Adage Capital Partners ✦ | 501.17K | n/a | $34.33M | 0.1% | n/c | 1 | SEC ↗ |
| 9 | Marshall Wace ✦ | 499.01K | n/a | $34.18M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | Renaissance Technologies ✦ | 222.40K | n/a | $15.23M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 133.67K | n/a | $9.16M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | AQR Capital Management ✦ | 105.43K | n/a | $7.22M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 13 | Gotham Asset Management ✦ | 5.29K | n/a | $362,038 | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Arrowstreet Capital ✦ | 3.91K | n/a | $268,000 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 1 shares, $2,540 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.